BrightPath Biotherapeutics Co (TSE:4594) Cyclically Adjusted Book per Share: 円77.13 (As of Mar. 2026)


TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
46 GF Score
Price 円50.00
GF Value 円4.64
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Cyclically Adjusted Book per Share?

BrightPath Biotherapeutics Co TSE:4594 +2.04% 46 Cyclically Adjusted Book per Share is 円77.13 as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 46/100 and a GF Value™ of 円4.64 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BrightPath Biotherapeutics Co's adjusted book value per share data for the fiscal year that ended in Mar. 2026 was 円17.053. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is 円77.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BrightPath Biotherapeutics Co's average Cyclically Adjusted Book Growth Rate was -8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-11), BrightPath Biotherapeutics Co's current stock price is 円 50.00. BrightPath Biotherapeutics Co's Cyclically Adjusted Book per Share for the fiscal year that ended in Mar. 2026 was 円77.13. BrightPath Biotherapeutics Co's Cyclically Adjusted PB Ratio of today is 0.65.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of BrightPath Biotherapeutics Co was 1.13. The lowest was 0.44. And the median was 0.67.


BrightPath Biotherapeutics Co  (TSE:4594) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BrightPath Biotherapeutics Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=50.00/77.13
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of BrightPath Biotherapeutics Co was 1.13. The lowest was 0.44. And the median was 0.67.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BrightPath Biotherapeutics Co Cyclically Adjusted Book per Share Related Terms


BrightPath Biotherapeutics Co Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Cyclically Adjusted Book per Share Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 84.55 84.06 77.13

BrightPath Biotherapeutics Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.55 0.00 84.06 0.00 77.13

TSE:4594 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Cyclically Adjusted PB Ratio falls into.


TSE:4594
46GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BrightPath Biotherapeutics Co's adjusted Book Value per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_Book=Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.053/112.7000*112.7000
=17.053

Current CPI (Mar. 2026) = 112.7000.

BrightPath Biotherapeutics Co Annual Data

Book Value per Share CPI Adj_Book
201703 139.714 98.100 160.507
201803 166.142 99.200 188.752
201903 121.352 99.700 137.175
202003 76.845 100.300 86.345
202103 69.614 99.900 78.534
202203 45.816 101.100 51.073
202303 24.925 104.400 26.907
202403 13.839 107.200 14.549
202503 10.222 111.100 10.369
202603 17.053 112.700 17.053

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of 円77.13 mean?
BrightPath Biotherapeutics Co (TSE:4594) has a Cyclically Adjusted Book per Share of 円77.13 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors.
Is BrightPath Biotherapeutics Co's Cyclically Adjusted Book per Share too high?
BrightPath Biotherapeutics Co's current Cyclically Adjusted Book per Share is 円77.13. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Cyclically Adjusted Book per Share compare to VRTX and REGN?
BrightPath Biotherapeutics Co's Cyclically Adjusted Book per Share of 円77.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Cyclically Adjusted Book per Share is 円77.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.64, compared to a current price of 円50.00 — trading 977.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is 円77.13. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Cyclically Adjusted Book per Share is 円77.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?

Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued. The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64. GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.

Key valuation signals for TSE:4594:

  • Cyclically Adjusted Book per Share: 円77.13
  • GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score

Get the complete analysis for TSE:4594

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円50.00
Price
円4.64
GF Value